EditorialEditorial
Open Access

Genomic medicine and cancer clinical trial in Thailand

Lucksamon Thamlikitkul, Napa Parinyanitikul and Virote Sriuranpong
Cancer Biology & Medicine January 2024, 21 (1) 10-15; DOI: https://doi.org/10.20892/j.issn.2095-3941.2023.0175

References

  1. 1.↵
    2. Berger MF,
    3. Mardis ER.
    The emerging clinical relevance of genomics in cancer medicine. Nat Rev Clin Oncol. 2018; 15: 353–65.
    OpenUrlCrossRefPubMed
  2. 2.↵
    2. Mosele F,
    3. Remon J,
    4. Mateo J,
    5. Westphalen CB,
    6. Barlesi F,
    7. Lolkema MP, et al.
    Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2020; 31: 1491–505.
    OpenUrlCrossRefPubMed
  3. 3.↵
    International Agency for Research on Cancer. Thailand Globocan 2020. 2021. Available from: https://gco.iarc.fr/today/data/factsheets/populations/764-thailand-fact-sheets.pdf.
  4. 4.↵
    2. Kohno T,
    3. Nakaoku T,
    4. Tsuta K,
    5. Tsuchihara K,
    6. Matsumoto S,
    7. Yoh K, et al.
    Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer. Transl Lung Cancer Res. 2015; 4: 156–64.
    OpenUrl
  5. 5.↵
    2. Mok TS,
    3. Wu YL,
    4. Thongprasert S,
    5. Yang CH,
    6. Chu DT,
    7. Saijo N, et al.
    Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361: 947–57.
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.↵
    2. Sriuranpong V,
    3. Chantranuwat C,
    4. Huapai N,
    5. Chalermchai T,
    6. Leungtaweeboon K,
    7. Lertsanguansinchai P, et al.
    High frequency of mutation of epidermal growth factor receptor in lung adenocarcinoma in Thailand. Cancer Lett. 2006; 239: 292–7.
    OpenUrlPubMedWeb of Science
  7. 7.↵
    2. Chantharasamee J,
    3. Poungvarin N,
    4. Danchaivijitr P,
    5. Techawatanawanna S.
    Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation. BMC Cancer. 2019; 19: 701.
    OpenUrl
  8. 8.↵
    2. Tan AC,
    3. Tan DSW.
    Targeted therapies for lung cancer patients with oncogenic driver molecular alterations. J Clin Oncol. 2022; 40: 611–25.
    OpenUrlCrossRefPubMed
  9. 9.↵
    2. Skoulidis F,
    3. Heymach JV.
    Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy. Nat Rev Cancer. 2019; 19: 495–509.
    OpenUrlCrossRefPubMed
  10. 10.↵
    2. Osarogiagbon RU,
    3. Yang PC,
    4. Sequist LV.
    Expanding the reach and grasp of lung cancer screening. Am Soc Clin Oncol Educ Book. 2023; 43: e389958.
  11. 11.↵
    2. Limsila T,
    3. Mitacek EJ,
    4. Caplan LS,
    5. Brunnemann KD.
    Histology and smoking history of lung cancer cases and implications for prevention in Thailand. Prev Med. 1994; 23: 249–52.
    OpenUrlCrossRefPubMedWeb of Science
  12. 12.↵
    2. Yin X,
    3. Chan CPY,
    4. Seow A,
    5. Yau W P,
    6. Seow WJ.
    Association between family history and lung cancer risk among Chinese women in Singapore. Sci Rep. 2021; 11: 21862.
  13. 13.↵
    2. Vermeulen R,
    3. Downward GS,
    4. Zhang J,
    5. Hu W,
    6. Portengen L,
    7. Bassig BA, et al.
    Constituents of Household Air Pollution and Risk of Lung Cancer among Never-Smoking Women in Xuanwei and Fuyuan, China. Environ Health Perspect. 2019; 127: 97001.
  14. 14.↵
    2. Hill W,
    3. Lim EL,
    4. Weeden CE,
    5. Lee C,
    6. Augustine M,
    7. Chen K, et al.
    Lung adenocarcinoma promotion by air pollutants. Nature. 2023; 616: 159–67.
    OpenUrlCrossRefPubMed
  15. 15.↵
    2. Chat-Uthai N,
    3. Vejvisithsakul P,
    4. Udommethaporn S,
    5. Meesiri P,
    6. Danthanawanit C,
    7. Wongchai Y, et al.
    Development of ultra-short PCR assay to reveal BRAF V600 mutation status in Thai colorectal cancer tissues. PLoS One. 2018; 13: e0198795.
  16. 16.↵
    2. Leelatian N,
    3. Boonchoo P,
    4. Wijitburaphat S,
    5. Moolsuwan K,
    6. Wongjaroen P,
    7. Chinnasang P, et al.
    Highly sensitive EGFR mutation detection by specific amplification of mutant alleles. Exp Mol Pathol. 2014; 96: 85–91.
    OpenUrl
  17. 17.↵
    2. Lertwilaiwittaya P,
    3. Roothumnong E,
    4. Nakthong P,
    5. Dungort P,
    6. Meesamarnpong C,
    7. Tansa-Nga W, et al.
    Thai patients who fulfilled NCCN criteria for breast/ovarian cancer genetic assessment demonstrated high prevalence of germline mutations in cancer susceptibility genes: implication to Asian population testing. Breast Cancer Res Treat. 2021; 188: 237–48.
    OpenUrlCrossRefPubMed
  18. 18.↵
    2. Lertwilaiwittaya P,
    3. Pithukpakorn M,
    4. Srinonprasert V,
    5. Tantai N,
    6. Maneeon S,
    7. Kraemer R, et al.
    O28: the health economics of gBRCA screening in high-risk breast cancer: how gBRCA became fully reimbursable in a middle-income country. Genet Med Open. 2023; 1: 100405.
  19. 19.↵
    2. Llovet JM,
    3. Kelley RK,
    4. Villanueva A,
    5. Singal AG,
    6. Pikarsky E,
    7. Roayaie S, et al.
    Hepatocellular carcinoma. Nat Rev Dis Primers. 2021; 7: 6.
    OpenUrl
  20. 20.↵
    2. Kamsa-ard S,
    3. Kamsa-ard S,
    4. Luvira V,
    5. Suwanrungruang K,
    6. Vatanasapt P,
    7. Wiangnon S.
    Risk factors for Cholangiocarcinoma in Thailand: a systematic review and meta-analysis. Asian Pac J Cancer Prev. 2018; 19: 605–14.
    OpenUrlCrossRefPubMed
  21. 21.↵
    2. Chaisaingmongkol J,
    3. Budhu A,
    4. Dang H,
    5. Rabibhadana S,
    6. Pupacdi B,
    7. Kwon SM, et al.
    Common molecular subtypes among Asian hepatocellular carcinoma and cholangiocarcinoma. Cancer Cell. 2017; 32: 57–70 e3.
    OpenUrlCrossRefPubMed
  22. 22.↵
    2. Wu YL,
    3. Herbst RS,
    4. Mann H,
    5. Rukazenkov Y,
    6. Marotti M,
    7. Tsuboi M.
    ADAURA: phase III, double-blind, randomized study of osimertinib versus placebo in EGFR mutation-positive early-stage NSCLC after complete surgical resection. Clin Lung Cancer. 2018; 19: e533–e6.
    OpenUrl
  23. 23.
    2. Soria JC,
    3. Tan DSW,
    4. Chiari R,
    5. Wu YL,
    6. Paz-Ares L,
    7. Wolf J, et al.
    First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet. 2017; 389: 917–29.
    OpenUrlCrossRefPubMed
  24. 24.↵
    2. Soria JC,
    3. Ohe Y,
    4. Vansteenkiste J,
    5. Reungwetwattana T,
    6. Chewaskulyong B,
    7. Lee KH, et al.
    Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018; 378: 113–25.
    OpenUrlCrossRefPubMed
  25. 25.↵
    2. Srimuninnimit V,
    3. Sriuranpong V,
    4. Suwanvecho S.
    Efficacy and safety of sorafenib in combination with gemcitabine in patients with advanced hepatocellular carcinoma: a multicenter, open-label, single-arm phase II study. Asia Pac J Clin Oncol. 2014; 10: 255–60.
    OpenUrl
  26. 26.↵
    2. Korphaisarn K,
    3. Danchaivijitr P,
    4. Reungwetwattana T,
    5. Chewaskulyong B,
    6. Thongthieang L,
    7. Chindaprasirt J, et al.
    Efficacy of combination docetaxel and nintedanib in advanced non-small cell lung cancer in Thailand: a multicenter study. Front Oncol. 2021; 11: 572740.
  27. 27.↵
    2. Teeyapun N,
    3. Luangdilok S,
    4. Pakvisal N,
    5. Sainamthip P,
    6. Mingmalairak S,
    7. Poovorawan N, et al.
    Immunogenicity of ChAdOx1-nCoV-19 vaccine in solid malignancy patients by treatment regimen versus healthy controls: a prospective, multicenter observational study. EClinicalMedicine. 2022; 52: 101608.
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section